Investor FAQ
Answers to frequently asked questions about Cardiol Therapeutics Inc. (TSX:CRDL).
Latest News?
Not disclosed in available filings.
Clinical Trials
CardiolRx™ is currently in clinical development for the treatment of heart disease, with two Phase II studies authorized by the FDA for recurrent pericarditis and acute myocarditis. A Phase I safety and pharmacokinetic study has been completed, showing that CardiolRx™ was safe and well tolerated at all dose levels.